{"id":"pegylated-interferon-ribavirin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Headache"},{"rate":"10-30%","effect":"Rash"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pegylated interferon is a type of protein that is used to stimulate the body's immune system to fight viral infections. Ribavirin, on the other hand, is an antiviral medication that works by inhibiting viral replication. When used together, they can help to reduce the amount of virus in the body and improve symptoms.","oneSentence":"Pegylated interferon works by stimulating the body's immune system to fight viral infections, while ribavirin is an antiviral medication that inhibits viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:59.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis C genotype 1"}]},"trialDetails":[{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT01340573","phase":"","title":"Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-23","conditions":"Chronic Hepatitis C","enrollment":3},{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT01120795","phase":"PHASE4","title":"Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy","status":"COMPLETED","sponsor":"Melbourne Health","startDate":"2004-02","conditions":"Chronic Hepatitis C","enrollment":55},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT01866930","phase":"PHASE3","title":"Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2013-07-11","conditions":"Chronic Hepatitis C Infection","enrollment":453},{"nctId":"NCT03067129","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Hepatitis C Virus (HCV)","enrollment":129},{"nctId":"NCT02087111","phase":"PHASE4","title":"Telaprevir in Genotype 3 HCV","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-04","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT01058512","phase":"PHASE2","title":"A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy","status":"COMPLETED","sponsor":"Cellectar Biosciences, Inc.","startDate":"2010-03","conditions":"Hepatitis C","enrollment":22},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT00078403","phase":"PHASE2","title":"Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections, Hepatitis C, Liver Disease","enrollment":333},{"nctId":"NCT00991289","phase":"PHASE2","title":"Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01","conditions":"HIV Infection, Hepatitis C Infection","enrollment":68},{"nctId":"NCT01482767","phase":"PHASE3","title":"Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"HIV Infections, Hepatitis C","enrollment":262},{"nctId":"NCT00051077","phase":"PHASE2","title":"Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B, Hepatitis C","enrollment":""},{"nctId":"NCT00015652","phase":"NA","title":"Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":24},{"nctId":"NCT00100581","phase":"NA","title":"Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":2},{"nctId":"NCT01587586","phase":"PHASE2","title":"Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2011-10-18","conditions":"Hepatitis C, Chronic","enrollment":107},{"nctId":"NCT01185028","phase":"PHASE1, PHASE2","title":"A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2010-08","conditions":"Hepatitis C Infection, HIV Infection","enrollment":8},{"nctId":"NCT00381953","phase":"PHASE3","title":"High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2003-02","conditions":"Hepatitis C","enrollment":33},{"nctId":"NCT02247401","phase":"PHASE3","title":"Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-11-04","conditions":"HCV, Hepatitis C Infection, Genotype 4","enrollment":160},{"nctId":"NCT02966795","phase":"PHASE3","title":"A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-01-25","conditions":"Hepatitis C Virus (HCV)","enrollment":84},{"nctId":"NCT01685203","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-08","conditions":"Hepatitis C, Chronic","enrollment":316},{"nctId":"NCT02541409","phase":"PHASE2","title":"Directly Observed Therapy for HCV in Chennai, India","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2015-09","conditions":"Hepatitis C, Chronic","enrollment":50},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT00943761","phase":"PHASE2","title":"A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10-23","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT02105701","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Hepatitis C Infection","enrollment":420},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT01821963","phase":"PHASE3","title":"Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-04","conditions":"Infection","enrollment":1},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT01741545","phase":"PHASE3","title":"Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-31","conditions":"Hepatitis C Virus","enrollment":71},{"nctId":"NCT00845676","phase":"PHASE4","title":"Treatment of Acute Hepatitis C Virus in HIV Co-Infection","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-03","conditions":"Hepatitis C, Human Immunodeficiency Virus, HIV Infections","enrollment":21},{"nctId":"NCT04382339","phase":"PHASE1, PHASE2","title":"Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2015-03","conditions":"Hepatitis C Virus Infection","enrollment":99},{"nctId":"NCT00086541","phase":"PHASE3","title":"Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-06","conditions":"Chronic Hepatitis C","enrollment":515},{"nctId":"NCT01364090","phase":"PHASE4","title":"A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":93},{"nctId":"NCT00230854","phase":"PHASE1","title":"Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2005-08","conditions":"Chronic Hepatitis C, Hepatitis, Viral, Human","enrollment":28},{"nctId":"NCT02247440","phase":"PHASE4","title":"HCV-HIV Co-infected Patient Cohort in Thailand","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2014-08","conditions":"Hepatitis C Infection, HIV","enrollment":18},{"nctId":"NCT03069365","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-28","conditions":"Hepatitis C Virus (HCV)","enrollment":101},{"nctId":"NCT00728936","phase":"PHASE1","title":"Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2007-09","conditions":"Hepatitis C","enrollment":58},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT01987453","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"HCV Infection","enrollment":100},{"nctId":"NCT02202980","phase":"PHASE2","title":"Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-08-04","conditions":"Chronic Hepatitis C","enrollment":273},{"nctId":"NCT01826981","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-04","conditions":"Chronic Hepatitis C","enrollment":359},{"nctId":"NCT01726517","phase":"PHASE2","title":"Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10","conditions":"Chronic Hepatitis C Virus","enrollment":100},{"nctId":"NCT01606800","phase":"PHASE4","title":"Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-01","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT00100659","phase":"PHASE3","title":"PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-12","conditions":"Chronic Hepatitis C","enrollment":114},{"nctId":"NCT01370642","phase":"PHASE3","title":"Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":294},{"nctId":"NCT00880763","phase":"PHASE2","title":"A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-20","conditions":"Hepatitis C","enrollment":90},{"nctId":"NCT00704184","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07-25","conditions":"Hepatitis C","enrollment":95},{"nctId":"NCT00704405","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03-27","conditions":"Hepatitis C, Chronic","enrollment":285},{"nctId":"NCT02358044","phase":"PHASE3","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT00793793","phase":"PHASE1","title":"Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"Hepatitis C, Chronic","enrollment":96},{"nctId":"NCT00136214","phase":"","title":"Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2004-03","conditions":"Hepatitis C","enrollment":22},{"nctId":"NCT01314261","phase":"PHASE2","title":"Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-03","conditions":"Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection","enrollment":37},{"nctId":"NCT00851890","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-03","conditions":"Chronic Hepatitis C Virus Infection","enrollment":30},{"nctId":"NCT01609933","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12-18","conditions":"Chronic Hepatitis C","enrollment":32},{"nctId":"NCT01854528","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-06","conditions":"Chronic Hepatitis C Infection","enrollment":148},{"nctId":"NCT01854697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":311},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT01355289","phase":"PHASE2","title":"Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-11","conditions":"Thrombocytopenia","enrollment":65},{"nctId":"NCT02021643","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-12-10","conditions":"Chronic HCV Infection","enrollment":687},{"nctId":"NCT02452814","phase":"","title":"Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-07","conditions":"HCV","enrollment":8},{"nctId":"NCT01439373","phase":"PHASE2","title":"Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-07","conditions":"Hepatitis C, Chronic","enrollment":16},{"nctId":"NCT03359746","phase":"PHASE4","title":"Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2017-12-15","conditions":"Hepatitis C","enrollment":40},{"nctId":"NCT02508090","phase":"","title":"Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-02","conditions":"Chronic Hepatitis C","enrollment":10},{"nctId":"NCT01659567","phase":"","title":"A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-04-06","conditions":"Hepatitis C, Chronic","enrollment":516},{"nctId":"NCT02476617","phase":"PHASE3","title":"Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06","conditions":"Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a","enrollment":25},{"nctId":"NCT02850289","phase":"","title":"APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-04","conditions":"Hepatitis C, Chronic","enrollment":385},{"nctId":"NCT00512278","phase":"PHASE2","title":"Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Nizar Zein","startDate":"2007-07","conditions":"Hepatitis C","enrollment":146},{"nctId":"NCT00803309","phase":"PHASE4","title":"Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients","status":"TERMINATED","sponsor":"HepNet Study House, German Liverfoundation","startDate":"2008-11","conditions":"Hepatitis C, Chronic","enrollment":99},{"nctId":"NCT02099604","phase":"PHASE3","title":"Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-04","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT01962441","phase":"PHASE3","title":"SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-24","conditions":"Hepatitis C","enrollment":601},{"nctId":"NCT01648140","phase":"PHASE2","title":"Dose Ranging of GSK2336805 in Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08-01","conditions":"Hepatitis C, Chronic","enrollment":286},{"nctId":"NCT00317746","phase":"PHASE3","title":"Trial of Citalopram for the Prevention of Depression","status":"COMPLETED","sponsor":"Marina Klein","startDate":"2006-11","conditions":"Depression, HIV Infections, Hepatitis C","enrollment":76},{"nctId":"NCT00239733","phase":"PHASE4","title":"Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-03","conditions":"Thrombocytopenia, Hepatitis C, HIV Infections","enrollment":6},{"nctId":"NCT03090035","phase":"PHASE3","title":"Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment","status":"COMPLETED","sponsor":"Sheikh Zayed Medical College","startDate":"2014-01-01","conditions":"Hepatitis C, Hepatitis C Relapse","enrollment":98},{"nctId":"NCT01482390","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-30","conditions":"Hepatitis C","enrollment":80},{"nctId":"NCT02006745","phase":"PHASE3","title":"Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2014-01","conditions":"HIV","enrollment":20},{"nctId":"NCT01153919","phase":"PHASE2","title":"Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2010-06-30","conditions":"Hepatitis C Infection, Thrombocytopenia","enrollment":27},{"nctId":"NCT00493805","phase":"PHASE4","title":"Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hepatitis C, Chronic, Insulin Resistance","enrollment":59},{"nctId":"NCT00423800","phase":"PHASE3","title":"Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis C, Chronic","enrollment":56},{"nctId":"NCT00959699","phase":"PHASE2","title":"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"HIV Infections, Hepatitis C, HCV Infection","enrollment":99},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00686777","phase":"PHASE4","title":"Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":75},{"nctId":"NCT00863109","phase":"","title":"Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Hepatitis C, Chronic, Genotype 1, HCV-1","enrollment":133},{"nctId":"NCT00759109","phase":"PHASE3","title":"Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-03","conditions":"Carcinoma, Hepatocellular","enrollment":150},{"nctId":"NCT00255034","phase":"PHASE4","title":"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":146},{"nctId":"NCT00378599","phase":"PHASE3","title":"Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis","enrollment":125},{"nctId":"NCT00255008","phase":"PHASE4","title":"Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT00265395","phase":"PHASE3","title":"Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-12","conditions":"Hepatitis C, Chronic","enrollment":1428},{"nctId":"NCT00686517","phase":"PHASE3","title":"Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-12","conditions":"Hepatitis C","enrollment":130},{"nctId":"NCT00978497","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-09","conditions":"HCV Infection","enrollment":97},{"nctId":"NCT01447446","phase":"","title":"An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":4442},{"nctId":"NCT00684268","phase":"PHASE2","title":"Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT01925183","phase":"PHASE4","title":"Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C","status":"COMPLETED","sponsor":"Markus Peck-Radosavljevic","startDate":"2013-08","conditions":"Hepatitis C, Chronic, HIV","enrollment":6},{"nctId":"NCT00277238","phase":"PHASE2","title":"CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02","conditions":"Hepatitis, Chronic Active","enrollment":113},{"nctId":"NCT01980290","phase":"","title":"Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2013-05","conditions":"Hepatitis, Chronic","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":358,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pegylated Interferon/ribavirin","genericName":"Pegylated Interferon/ribavirin","companyName":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","companyId":"national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon alfa-2b is used to treat conditions related to Hepatitis C, including Chronic Hepatitis C, Acute Hepatitis C, and Chronic Hepatitis C Infection. It works by interacting with proteins, specifically as a protein modality, to exert its effects.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}